Prevention measures for MRSA and their implementation;MRSA-präventionsmaßnahmen und deren umsetzung

Chemotherapie Journal

Volumn 18, Issue 3, 2009, Pages 93-95

  Chaberny, Iris F ^a   Gastmeier, Petra ^b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Infection prevention; MRSA epidemiology; MRSA KISS; Surveillance

Indexed keywords

ANTIBIOTIC RESISTANCE; BACTEREMIA; COST BENEFIT ANALYSIS; DISEASE CARRIER; HOSPITAL INFECTION; HUMAN; INFECTION CONTROL; LENGTH OF STAY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORTALITY; REVIEW; SEPSIS;

EID: 68849110380     PISSN: 09406735     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. Abramson MA, Sexton DJ. Nosocomial methicillin-resistant and methicillin-susceptible Staphylococcus aureus primary bacteremia: at what costs? Infect Control Hosp Epidemiol 1999;20:408-411
2. Chaberny IF, Sohr D, Ruden H, Gastmeier P. Development of a surveillance system for methicillin-resistant Staphylococcus aureus in German hospitals. Infect Control Hosp Epidemiol 2007;28:446-452 (Pubitemid 46658058)
3. Chaix C, Durand-Zaleski I, Alberti C, Brun-Buisson C. Control of endemic methicillin-resistant Staphylgcoccus aureus: a cost-benefit analysis in an intensive care unit. JAMA 1999;282:1745-1751 (Pubitemid 29533605)
4. Cosgrove SE. The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs. Clin Infect Dis 2006;42(Suppl 2):S82-9.
5. Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, et al. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis 2003;36:53-59 (Pubitemid 36099097)
6. Cosgrove SE, Qi Y, Kaye KS, Harbarth S, et al. The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges. Infect Control Hosp Epidemiol 2005;26:166-174 (Pubitemid 40445022)
7. Davis KA, Stewart JJ, Crouch HK, Florez CE, et al. Methicillin-resistant Staphylococcus aureus (MRSA) nares colonization at hospital admission and its effect on subsequent MRSA infection. Clin Infect Dis 2004;39:776-782
8. Engemann JJ, Carmeli Y, Cosgrove SE, Fowler VG, et al. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin Infect Dis 2003;36:592-598 (Pubitemid 36259564)
9. Gastmeier P, Chaberny IF. Which rate describes the MRSA situation appropriately? Dtsch Med Wochenschr 2007;132:1480-1482
10. Gould IM. Costs of hospital-acquired methicillin-resistant Staphylococcus aureus (MRSA) and its control. Int J Antimicrob Agents 2006;28:379-384 (Pubitemid 44636188)
11. Henderson RJ, Williams RE. Nasal carriage of Staphylococci and post-operative Staphylococcal wound infection. J Clin Pathol 1963;16:452-456
12. Kim T, Oh PI, Simor AE. The economic impact of methicillin-resistant Staphylococcus aureus in Canadian hospitals. Infect Control Hosp Epidemiol 2001;22:99-104. (Pubitemid 32157160)
13. Kopp BJ, Nix DE, Armstrong EP. Clinical and economic analysis of methicillin-susceptible and -resistant Staphylococcus aureus infections. Ann Pharmacother 2004;38:1377-1382
14. Kresken M, Hafner D, Schmitz F-J, Wichelhaus TA. Resistenzsituation bei klinisch wichtigen Infektionserregern gegenüber Antibiotika in Deutschland und im mitteleuropäischen Raum. Bericht über die Ergebnisse einer multizentrischen Studie der Arbeitsgemeinschaft Empfindlichkeitsprüfungen & Resistenz der Paul-Ehrlich-Gesellschaft für Chemotherapie e.V. aus dem Jahre 2004. Rheinbach: Antiinfectives Intelligence, 2006:14-15
15. Lodise TP, McKinnon PS. Clinical and economic impact of methicillin resistance in patients with Staphylococcus aureus bacteremia. Diagn Microbiol Infect Dis 2005;52:113-122 (Pubitemid 40826937)
16. Mattner F, Biertz F, Hecker H, to Baben-Yang M, et al. Long-term MRSA-persistence determined by MRSA surveillance of subsequent hospital stays. Int J Med Microbiol 2007;297(Suppl 1):72.
17. Melzer M, Eykyn SJ, Gransden WR, Chinn S. Is methicillin-resistant Staphylococcus aureus more virulent than methicillin-susceptible S. aureus? A comparative cohort study of British patients with nosocomial infection and bacteremia. Clin Infect Dis 2003;37:1453-1460 (Pubitemid 37494672)
18. Merrer J, Santoli F, Appere de Vecchi C, Tran B, et al. "Colonization pressure" and risk of acquisition of methicillin-resistant Staphylococcus aureus in a medical intensive care unit. Infect Control Hosp Epidemiol 2000;21:718-723 (Pubitemid 30841254)
19. Meyer E, Schwab F, Pollitt A, Trautmann M. Resistance rates in ICUs: interpretation and pitfalls. J Hosp Infect 2007;65:84-85 (Pubitemid 44939365)
20. Papia G, Louie M, Tralla A, Johnson C, et al. Screening high-risk patients for methicillin-resistant Staphylococcus aureus on admission to the hospital: is it cost effective? Infect Control Hosp Epidemiol 1999;20:473-477
21. Pittet D, Tarara D, Wenzel RP. Nosocomial bloodstream infection in critically ill patients. Excess length of stay, extra costs, and attributable mortality. JAMA 1994;271:1598-1601.
22. Reichardt C, Chaberny IF, Deegener K, Gastmeier P. Nosocomial MRSA infections - at what costs? Int J Med Microbiol 2006;296(Suppl 3):56.
23. Rosenthal EJK. Epidemiologie von Septikämie-Erregern. Dtsch Med Wochenschr 2002;127:2435-2440
24. Tiemersma EW, Bronzwaer SL, Lyytikainen O, Degener JE, et al. Methicillin-resistant Staphylococcus aureus in Europe, 1999-2002. Emerg Infect Dis 2004;10:1627-1634
25. von Eiff C, Becker K, Machka K, Stammer H, et al. Nasal carriage as a source of Staphylococcus aureus bacteremia. Study Group. N Engl J Med 2001;344:11-16 (Pubitemid 32064839)
26. Wenzel RP, Perl TM. The significance of nasal carriage of Staphylococcus aureus and the incidence of postoperative wound infection. J Hosp Infect 1995;31:13-24.
27. Wernitz MH, Keck S, Swidsinski S, Schulz S, et al. Cost analysis of a hospital-wide selective screening programme for methicillin-resistant Staphylococcus aureus (MRSA) carriers in the context of diagnosis related groups (DRG) payment. Clin Microbiol Infect 2005;11:466-471 (Pubitemid 40744393)
28. Whitby M, McLaws ML, Berry G. Risk of death from methicillin-resistant Staphylococcus aureus bacteraemia: a meta-analysis. Med J Aust 2001;175:264-267 (Pubitemid 32851061)